Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3

Status

Completed 81Recruiting 19Terminated 18Active not recruiting 13Unknown 12Withdrawn 6Not yet recruiting 4Suspended 1

Sponsor Class

OTHER 3INDUSTRY 2NIH 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Genitourinary 2CNS 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Glioblastoma 2Carcinoma, Renal Cell 2Neoplasms 1Gliosarcoma 1Glioma 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 128Cisplatin 119Radiotherapy 111pembrolizumab 110Paclitaxel 96Gemcitabine 96Carboplatin 96Nivolumab 76Magnetic Resonance Spectroscopy 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Doxorubicin 52fludarabine 51Biopsy 48durvalumab 44Cytarabine 44Drug Therapy 43Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Lenalidomide 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Withdrawn × Interventional × Axitinib × Clear all
NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT05263609 2022-08-02

Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib

University of Oklahoma

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell

NCT04197219 2020-11-05

Pembrolizumab With Axitinib in Recurrent Endometrial Cancer

Case Comprehensive Cancer Center

Phase 2 Withdrawn
Gynecologic

Endometrial Neoplasms

NCT03275558 2018-07-19

Clinical Trial of the Use of the Nasal Spray of Patients With Recurrence of Glioblastoma

Center Trials & Treatment

Phase 1 Withdrawn
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

NCT00386555 2012-08-09

A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.

Arog Pharmaceuticals, Inc.

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01441388 2011-12-20

A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.

Pfizer

Phase 1 Withdrawn
CNSGastrointestinalGenitourinary

Carcinoma, Renal Cell, Glioblastoma, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡